메뉴 건너뛰기




Volumn 15, Issue 10, 2015, Pages 2655-2664

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses

Author keywords

Immune modulation; immunosuppression; kidney transplantation; nephrology

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NYSTATIN; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; RAPAMYCIN;

EID: 84941932502     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13327     Document Type: Article
Times cited : (124)

References (33)
  • 1
    • 79959355125 scopus 로고    scopus 로고
    • Human cytomegalovirus and kidney transplantation: A clinician's update
    • De Keyzer K, Van Laecke S, Peeters P, Vanholder R., Human cytomegalovirus and kidney transplantation: A clinician's update. Am J Kidney Dis 2011; 58: 118-126.
    • (2011) Am J Kidney Dis , vol.58 , pp. 118-126
    • De Keyzer, K.1    Van Laecke, S.2    Peeters, P.3    Vanholder, R.4
  • 2
    • 84877965931 scopus 로고    scopus 로고
    • CMV: Prevention, diagnosis and therapy
    • Kotton CN,. CMV: Prevention, diagnosis and therapy. Am J Transplant 2013; 13: 24-40.
    • (2013) Am J Transplant , vol.13 , pp. 24-40
    • Kotton, C.N.1
  • 3
    • 84883455574 scopus 로고    scopus 로고
    • Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation
    • Kotton CN, Kumar D, Caliendo AM, et al., Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360.
    • (2013) Transplantation , vol.96 , pp. 333-360
    • Kotton, C.N.1    Kumar, D.2    Caliendo, A.M.3
  • 4
    • 84903401627 scopus 로고    scopus 로고
    • Emerging cytomegalovirus management strategies after solid organ transplantation: Challenges and opportunities
    • Beam E, Dioverti V, Razonable RR., Emerging cytomegalovirus management strategies after solid organ transplantation: Challenges and opportunities. Curr Infect Dis Rep 2014; 16: 419.
    • (2014) Curr Infect Dis Rep , vol.16 , pp. 419
    • Beam, E.1    Dioverti, V.2    Razonable, R.R.3
  • 5
    • 77950926374 scopus 로고    scopus 로고
    • International consensus guidelines on the management of cytomegalovirus in solid organ transplantation
    • Kotton CN, Kumar D, Caliendo AM, et al., International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
    • (2010) Transplantation , vol.89 , pp. 779-795
    • Kotton, C.N.1    Kumar, D.2    Caliendo, A.M.3
  • 6
    • 82755189443 scopus 로고    scopus 로고
    • GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients
    • de la Torre-Cisneros J, Fariñas MC, Castõn JJ, et al., GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735-758.
    • (2011) Enferm Infecc Microbiol Clin , vol.29 , pp. 735-758
    • De La Torre-Cisneros, J.1    Fariñas, M.C.2    Castõn, J.J.3
  • 7
    • 84904696541 scopus 로고    scopus 로고
    • Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation
    • Santos CAQ, Brennan DC, Fraser VJ, Olsen MA., Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation 2014; 98: 187-194.
    • (2014) Transplantation , vol.98 , pp. 187-194
    • Santos, C.A.Q.1    Brennan, D.C.2    Fraser, V.J.3    Olsen, M.A.4
  • 8
    • 40749108069 scopus 로고    scopus 로고
    • Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation
    • Arthurs SK, Eid AJ, Pedersen RA, et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846.
    • (2008) Clin Infect Dis , vol.46 , pp. 840-846
    • Arthurs, S.K.1    Eid, A.J.2    Pedersen, R.A.3
  • 9
    • 84925021519 scopus 로고    scopus 로고
    • Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment
    • Stern M, Hirsch H, Cusini A, et al., Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98: 1013-1018.
    • (2014) Transplantation , vol.98 , pp. 1013-1018
    • Stern, M.1    Hirsch, H.2    Cusini, A.3
  • 10
    • 13144268553 scopus 로고    scopus 로고
    • Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report
    • Preiksaitis JK, Brennan DC, Fishman J, Allen U., Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-227.
    • (2005) Am J Transplant , vol.5 , pp. 218-227
    • Preiksaitis, J.K.1    Brennan, D.C.2    Fishman, J.3    Allen, U.4
  • 11
    • 37549024633 scopus 로고    scopus 로고
    • Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation
    • Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V., Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
    • (2008) Am J Transplant , vol.8 , pp. 69-77
    • Reischig, T.1    Jindra, P.2    Hes, O.3    Svecova, M.4    Klaboch, J.5    Treska, V.6
  • 12
    • 84897082126 scopus 로고    scopus 로고
    • The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients
    • Roman A, Manito N, Maria Campistol, J, et al., The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev 2014; 28: 84-91.
    • (2014) Transplant Rev , vol.28 , pp. 84-91
    • Roman, A.1    Manito, N.2    Campistol, M.J.3
  • 13
    • 33744473322 scopus 로고    scopus 로고
    • Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials
    • Webster AC, Lee VWS, Chapman JR, Craig JC., Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
    • (2006) Transplantation , vol.81 , pp. 1234-1248
    • Webster, A.C.1    Lee, V.W.S.2    Chapman, J.R.3    Craig, J.C.4
  • 14
    • 84857194014 scopus 로고    scopus 로고
    • Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials
    • Brennan DC, Legendre C, Patel D, et al., Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453-2462.
    • (2011) Am J Transplant , vol.11 , pp. 2453-2462
    • Brennan, D.C.1    Legendre, C.2    Patel, D.3
  • 15
    • 84872085198 scopus 로고    scopus 로고
    • Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis
    • Andrassy J, Hoffmann VS, Rentsch M, et al., Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis. Transplantation 2012; 94: 1208-1217.
    • (2012) Transplantation , vol.94 , pp. 1208-1217
    • Andrassy, J.1    Hoffmann, V.S.2    Rentsch, M.3
  • 16
    • 84906246466 scopus 로고    scopus 로고
    • A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients
    • Lim WH, Eris J, Kanellis J, et al., A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 2014; 14: 2106-2119.
    • (2014) Am J Transplant , vol.14 , pp. 2106-2119
    • Lim, W.H.1    Eris, J.2    Kanellis, J.3
  • 17
    • 84862290097 scopus 로고    scopus 로고
    • Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor- based immunosuppressive therapy in de novo renal transplant recipients
    • Nashan B, Gaston R, Emery V, et al., Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor- based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085.
    • (2012) Transplantation , vol.93 , pp. 1075-1085
    • Nashan, B.1    Gaston, R.2    Emery, V.3
  • 18
    • 84859711356 scopus 로고    scopus 로고
    • Everolimus plus early tacrolimus minimization: A phase III, randomized, open label, multicentre trials in enal transplantation
    • Langer RM, Hené R, Vitko S, et al., Everolimus plus early tacrolimus minimization: A phase III, randomized, open label, multicentre trials in enal transplantation. Transplant Int 2012; 25: 592-602.
    • (2012) Transplant Int , vol.25 , pp. 592-602
    • Langer, R.M.1    Hené, R.2    Vitko, S.3
  • 19
    • 37349034394 scopus 로고    scopus 로고
    • Reduced exposure to calcineurin inhibitors in renal transplantation
    • Ekberg H, Tedesco-Silva H, Demirbas A, et al., Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
    • (2007) N Engl J Med , vol.357 , pp. 2562-2575
    • Ekberg, H.1    Tedesco-Silva, H.2    Demirbas, A.3
  • 20
    • 75749119257 scopus 로고    scopus 로고
    • Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups
    • Sis B, Mengel M, Haas M, et al., Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
    • (2010) Am J Transplant , vol.10 , pp. 464-471
    • Sis, B.1    Mengel, M.2    Haas, M.3
  • 22
    • 72449147738 scopus 로고    scopus 로고
    • The multifunctional role of mTOR in innate immunity: Implications for transplant immunity
    • Saemann MD, Haidinger M, Hecking M, Horl WH, Weichhart T., The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009; 9: 2655-2661.
    • (2009) Am J Transplant , vol.9 , pp. 2655-2661
    • Saemann, M.D.1    Haidinger, M.2    Hecking, M.3    Horl, W.H.4    Weichhart, T.5
  • 23
    • 79953814668 scopus 로고    scopus 로고
    • Rapamycin increases the yield and effector function of human gammadelta T cells stimulated in vitro
    • Li H, Pauza CD., Rapamycin increases the yield and effector function of human gammadelta T cells stimulated in vitro. Cancer Immunol Immunother 2011; 60: 361-370.
    • (2011) Cancer Immunol Immunother , vol.60 , pp. 361-370
    • Li, H.1    Pauza, C.D.2
  • 24
    • 79952844950 scopus 로고    scopus 로고
    • The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection
    • Clippinger AJ, Maguire TG, Alwine JC., The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol 2011; 85: 3930-3939.
    • (2011) J Virol , vol.85 , pp. 3930-3939
    • Clippinger, A.J.1    Maguire, T.G.2    Alwine, J.C.3
  • 25
    • 67650074206 scopus 로고    scopus 로고
    • MTOR regulates memory CD8 T-cell differentiation
    • Araki K, Turner AP, Shaffer VO, et al., mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
    • (2009) Nature , vol.460 , pp. 108-112
    • Araki, K.1    Turner, A.P.2    Shaffer, V.O.3
  • 26
    • 77956893188 scopus 로고    scopus 로고
    • Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses
    • Ferrer IR, Wagener ME, Robertson JM, et al., Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010; 185: 2004-8.
    • (2010) J Immunol , vol.185 , pp. 2004-2008
    • Ferrer, I.R.1    Wagener, M.E.2    Robertson, J.M.3
  • 27
    • 77950882839 scopus 로고    scopus 로고
    • Interleukin 2 receptor antagonists for kidney transplant recipients
    • Webster AC, Ruster LP, McGee R, et al., Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; 2010.
    • (2010) Cochrane Database Syst Rev , vol.2010
    • Webster, A.C.1    Ruster, L.P.2    McGee, R.3
  • 28
    • 84901912546 scopus 로고    scopus 로고
    • Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients
    • 16
    • Lee YM, Kim YH, Han DJ, et al., Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients. Transplant Infect Dis 2014; 16: 397-402.
    • (2014) Transplant Infect Dis , pp. 397-402
    • Lee, Y.M.1    Kim, Y.H.2    Han, D.J.3
  • 29
    • 84873409207 scopus 로고    scopus 로고
    • Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling
    • Egli A, Kumar D, Broscheit C, O'Shea D, Humar A., Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 2013; 95: 448-455.
    • (2013) Transplantation , vol.95 , pp. 448-455
    • Egli, A.1    Kumar, D.2    Broscheit, C.3    O'Shea, D.4    Humar, A.5
  • 30
    • 84876290338 scopus 로고    scopus 로고
    • Randomized trial of everolimus- facilitated calcineurin inhibitor minimization over 24 months in renal transplantation
    • Cibrik D, Silva HT Jr., Vathsala A, et al., Randomized trial of everolimus- facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013; 95: 933-942.
    • (2013) Transplantation , vol.95 , pp. 933-942
    • Cibrik, D.1    Silva, H.T.2    Vathsala, A.3
  • 31
    • 77957583305 scopus 로고    scopus 로고
    • Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial (vol 23, pg 1084 JT 2010)
    • Dantal J, Berthoux F, Moal MC, et al., Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial (vol 23, pg 1084 JT 2010). Transplant Int 2012; 25: 1084-1093.
    • (2012) Transplant Int , vol.25 , pp. 1084-1093
    • Dantal, J.1    Berthoux, F.2    Moal, M.C.3
  • 32
    • 84941942529 scopus 로고    scopus 로고
    • Efficacy and safety of everolimus with low-dose tacrolimus in de Novo renal transplant recipients: 12-month randomized study
    • Qazi Y, Shaffer D, Kaplan B, et al., Efficacy and safety of everolimus with low-dose tacrolimus in de Novo renal transplant recipients: 12-month randomized study. Am J Transplant 2014; 14: 80.
    • (2014) Am J Transplant , vol.14 , pp. 80
    • Qazi, Y.1    Shaffer, D.2    Kaplan, B.3
  • 33
    • 84978264145 scopus 로고    scopus 로고
    • Influence of induction therapy on the efficacy of everolimus vs mycophenolate based regimen in de novo renal transplant recipients
    • Vincenti F, Qazi Y, Kaplan B, et al., Influence of induction therapy on the efficacy of everolimus vs mycophenolate based regimen in de novo renal transplant recipients. Am J Transplant 2014; 14: 539-540.
    • (2014) Am J Transplant , vol.14 , pp. 539-540
    • Vincenti, F.1    Qazi, Y.2    Kaplan, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.